CrestecBio raises US$1.92M seed for stroke neuroprotection drug
What's the deal? CrestecBioDealroom has a profile for this one. Try Dealroom →, a University of Tsukuba spinout developing polymer-based drugs to protect the brain and organs, has closed a US$1.92M (roughly $1.7M) seed round. The funding came from Realtech Fund (run by UntroD Capital Japan), Japan Science and Technology AgencyDealroom has a profile for this one. Try Dealroom → (JST), KSPDealroom has a profile for this one. Try Dealroom →'s NextG fund, and Newsight Tech AngelsDealroom has a profile for this one. Try Dealroom →' NTA fund. The company will use the capital to push its lead candidate — a neuroprotective drug called CTB211 for ischaemic stroke — toward clinical trials, accelerating preclinical studies and manufacturing prep.
Founded in December 2021 by neurosurgeon and emergency medicine physician Aiki Marushima, CrestecBio builds on polymer therapeutics research conducted at the University of Tsukuba. CTB211 is a micelle-structured polymer roughly 20–30nm in size that scavenges reactive oxygen species (ROS) to protect nerve cells.
Why now? Mechanical thrombectomy — a catheter-based procedure to remove blood clots in the brain — has spread rapidly since 2015, cutting stroke mortality. But more than 50% of patients who undergo the procedure still face severe disability or death, largely due to reperfusion injury caused by ROS flooding back into brain tissue once blood flow resumes. No approved drug currently addresses this problem.
Stroke strikes about 300,000 people a year in Japan and 800,000 in the US, ranking as the third leading cause of death in Japan and second worldwide. The unmet need is enormous — and growing as thrombectomy becomes standard care.
What could go wrong? Neuroprotection in stroke has a long, painful history. Dozens of candidate drugs have failed in clinical trials over the past three decades, earning the field a reputation as a graveyard for drug developers. Translating promising preclinical results into human efficacy remains a steep challenge.
CrestecBio is still at the preclinical stage, meaning it faces years of development, regulatory hurdles, and substantial capital needs before any product could reach patients. A US$1.92M seed round is modest for drug development — the company will almost certainly need significantly larger follow-on funding.
The signal: With JST — a government and non-profit investor — anchoring the round alongside corporate and fund backers, CrestecBio's seed reflects Japan's layered public-private model for de-risking university spinout drug development. The deal also highlights a niche opening in stroke care: as mechanical thrombectomy becomes the standard intervention, companion neuroprotective therapies represent a largely unoccupied market that investors are beginning to price in, even at the preclinical stage.
Read more: PR TIMES
